A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
comorbidity index (HCT-CI) scores > 2 (72% vs 37%, p ¼ 0.009), and pre-NMAT platelets < 25k/uL (33% vs 8%, p ¼ 0.01). In an unadjusted comparison, OS and PFS favored the RIT pts, but the differences were not statistically significant (hazard ratio [HR] for OS ¼ 0.60, 95% confidence interval [CI]: 0.3-1.4, p ¼ 0.24; HR for PFS ¼ 0.75, 95% CI: 0.4-1.5, p ¼ 0.41). However, after adjusting for significant differences between these groups, outcomes for the RIT-treated group were significantly betterdoi:10.1016/j.bbmt.2013.12.088 fatcat:52wiie7nmzbkdh462hrcsd6nze